Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SAVA 
Cassava Sciences Inc (SAVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: SAVA (1-star) is a SELL. SELL since 3 days. Profits (-11.59%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.25% | Avg. Invested days 28 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 84.54M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) - | Beta -2.02 | 52 Weeks Range 1.15 - 42.20 | Updated Date 06/30/2025 |
52 Weeks Range 1.15 - 42.20 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.59 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -59.03% | Return on Equity (TTM) -70.6% |
Valuation
Trailing PE - | Forward PE 151.52 | Enterprise Value -35631025 | Price to Sales(TTM) - |
Enterprise Value -35631025 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -8.26 | Shares Outstanding 48307900 | Shares Floating 43475174 |
Shares Outstanding 48307900 | Shares Floating 43475174 | ||
Percent Insiders 12.79 | Percent Institutions 33.05 |
Analyst Ratings
Rating - | Target Price 2 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cassava Sciences Inc
Company Overview
History and Background
Cassava Sciences, Inc. (SAVA) was founded in 1998. Initially focused on detecting diseases earlier, it has shifted focus to developing drugs for neurodegenerative diseases, particularly Alzheimer's disease. Milestones include clinical trial phases for Simufilam, its lead drug candidate, and facing scrutiny over its clinical trial data.
Core Business Areas
- Drug Development: Focuses on developing and commercializing pharmaceutical products for neurodegenerative diseases, with a primary focus on Alzheimer's disease.
Leadership and Structure
Remi Barbier is the President and CEO. The company has a board of directors overseeing its operations. The organizational structure is typical of a small biotech firm, emphasizing research and development.
Top Products and Market Share
Key Offerings
- Simufilam: Simufilam is an investigational drug for Alzheimer's disease. As it's still in clinical trials, there's no market share or revenue currently. Competitors include Biogen (BIIB) with Leqembi and Eli Lilly (LLY) with Donanemab (pending FDA approval).
Market Dynamics
Industry Overview
The pharmaceutical industry focused on Alzheimer's disease is highly competitive, with significant unmet medical needs and high potential rewards. The area attracts major pharmaceutical companies and smaller biotech firms.
Positioning
Cassava Sciences is a smaller player attempting to compete with larger, established pharmaceutical companies in the Alzheimer's space. Its competitive advantage, if any, hinges on positive trial results for Simufilam and a novel mechanism of action.
Total Addressable Market (TAM)
The global Alzheimer's disease market is expected to reach hundreds of billions of dollars in the coming years. Cassava Sciences is positioned to capture a portion of this TAM if Simufilam proves effective and gains regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action for Simufilam (if proven)
- Focus on a high-need area (Alzheimer's)
- Strong patent portfolio (if valid)
Weaknesses
- Reliance on a single drug candidate
- Limited financial resources compared to larger competitors
- Controversies surrounding clinical trial data
- Uncertain regulatory pathway
Opportunities
- Positive clinical trial results leading to FDA approval
- Partnerships with larger pharmaceutical companies
- Expansion into other neurodegenerative diseases
Threats
- Failure of Simufilam in clinical trials
- Regulatory rejection
- Competition from other Alzheimer's drugs
- Negative impact of controversies on stock price and funding
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- ABBV
- NVS
Competitive Landscape
Cassava Sciences faces an uphill battle against larger, well-funded competitors with established market presence. Its success hinges on demonstrating Simufilam's efficacy and safety in well-designed clinical trials.
Growth Trajectory and Initiatives
Historical Growth: There's no historical revenue growth due to being a pre-revenue company.
Future Projections: Future growth depends entirely on the successful development and commercialization of Simufilam.
Recent Initiatives: Focus on completing clinical trials for Simufilam and addressing concerns raised about data integrity.
Summary
Cassava Sciences is a high-risk, high-reward biotech company focused on Alzheimer's disease. Its future depends heavily on the success of Simufilam's clinical trials. The controversies surrounding the company's data present a significant challenge. Financial stability and successful trial outcomes are crucial for the company's long-term viability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Financial News Outlets (e.g., Yahoo Finance, Bloomberg)
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. The information provided is based on publicly available data and may be subject to change. Investing in biotech companies is inherently risky, and investors should conduct their own thorough research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cassava Sciences Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2000-07-14 | CEO, President & Director Mr. Richard Jon Barry | ||
Sector Healthcare | Industry Biotechnology | Full time employees 30 | Website https://www.cassavasciences.com |
Full time employees 30 | Website https://www.cassavasciences.com | ||
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.